PhD Scientific Days 2024
Budapest, 9-10 July 2024
Poster Session P - Conservative Medicine
Investigation of the Effects of Tumour Necrosis Factor Inhibitors on the Risk of Cardiovascular Events in Immune-Mediated Inflammatory Diseases
Előadó neve
Dr. Vámosi-Galajda, Noémi Ágnes
Neptun code
Q1FEQZ
Előadó munkahelye
Department of Dermatology, Venereology and Dermatooncology, Semmelweis University
Előadó telefonszáma
+36304196934
Előadó e-mail címe
noemigalajda@gmail.com
Az előadás címe
Investigation of the Effects of Tumour Necrosis Factor Inhibitors on the Risk of Cardiovascular Events in Immune-Mediated Inflammatory Diseases
Szerző(k) neve és munkahelye
Noémi Ágnes Galajda1,2, Fanni Adél Meznerics1,2, Péter Mátrai3, Péter Fehérvári2,4, Anna Sára Lengyel2,5,6, Mária Veronika Kolonics2,5, Zoltán Sipos3, Lajos Vince Kemény2,5,6, Dezső Csupor2,7, Péter Hegyi2,3,8, András Bánvölgyi2,5, Péter Holló5
1: Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
2: Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
3: Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
4: Department of Biostatistics, University of Veterinary Medicine, Budapest, Hungary
5: Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
6: HCEMM-SU Translational Dermatology Research Group, Department of Physiology, Semmelweis University, Budapest, Hungary
7: Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary
8: Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary
Bemutatás módja
Poszter
Szekció
Poster Session P - Conservative Medicine
Language of the presentation
English
Preferred session
Conservative Medicine
Összefoglaló szövege
Introduction
Immune-mediated inflammatory diseases (IMIDs) like psoriasis and psoriatic arthritis (Pso, PsA), rheumatoid arthritis (RA) and inflammatory bowel diseases (IBDs) are associated with an increased risk of cardiovascular (CV) events. TNF inhibitors (TNFis) may reduce the risk of atherosclerotic CV disease (ASCVD) events, potentially more effectively than first-line conventional treatments, which do not act on immunological pathways thought to be shared with atherosclerosis. While TNFis are presumably associated with reducing the risk of ASCVD events, their impact on heart failure (HF) is controversial. According to the current professional consensus, TNFis are potential risk factors for worsening HF.
Aims
We aimed to compare TNFi- and conventional systemic non-biological (CSNBs) -treated cohorts on the risk of ASCVD events. Furthermore, to investigate the effects of TNFis on the risk of development of de novo and worsening of heart failure (HFdn and HFw).
Method
Two projects with the methodology of systemic reviews and meta-analyses were conducted, including the results of randomized and non-randomized studies. In the first project, articles investigating the incidence of ASCVD events, with major adverse cardiovascular events (MACE) as a primary outcome, in TNFi versus CSNB groups were eligible. The second project investigated the incidence of HF in TNFi-treated versus non-TNFi-treated patients. Random-effect meta-analyses were performed with pooled risk estimates and their 95% confidence intervals (CI).
Results
The first systematic search yielded 8724, while the second generated 6434 hits. From both pools, 29 studies were eligible separately for the quantitative analyses. Analyses of the first project showed that TNFis had a significantly lower risk of MACE than the CSNB group [Hazard Ratio= 0.74, 95% CI 0.58–0.95). The results of the second meta-analysis presented that TNFis were not associated with a higher risk of HFw or HFdn. The pooled results of studies with real-world data suggest that TNFi may also have a risk-reducing role in developing HFdn.
Conclusion
Prior use of TNFis instead of CSNBs in the therapeutic sequence can be recommended to decrease the risk of ASCVD burden in IMIDs. The findings of the second meta-analysis may allow broader use of TNFis in IMID populations with CV diseases.
Funding
SE 250+ Excellence PhD Scholarship
University
Semmelweis University
Other university, not listed above
-
Supervisor
Prof. Dr. Péter Holló, Dr. András Bánvölgyi
Publication of my abstract
I do not give consent to the publication of my abstract on the website of the congress.
Kind
Szabad
Status
elfogadva
Accepted presentation method
poszter
Előadás fájl jóváhagyás
nem rendelkezett róla
Előadó
7437
Start
16:25
End
16:28